Merck Completes Cash Acquisition of Cidara
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Merck (MRK) announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics (CDTX). Merck intends to complete the acquisition through a merger of Merck's wholly owned subsidiary with and into Cidara, with Cidara being the surviving corporation, in which all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $221.50 offer price per common share, without interest and subject to deduction for any required tax withholding. After the completion of the merger, Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market. The acquisition is expected to be accounted for as an asset acquisition, resulting in a charge that will increase 2026 research and development expenses by approximately $9B or approximately $3.65 per share, included in GAAP and non-GAAP results. Additionally, GAAP and non-GAAP EPS are expected to be negatively impacted by approximately 30c per share in the first 12 months, representing costs associated with advancing CD388 and costs of financing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 120.240
Low
95.00
Averages
119.53
High
139.00
Current: 120.240
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Declare Quarterly Dividends
- Deere Dividend: Deere's Board of Directors declared a quarterly dividend of $1.62 per share, payable on August 10, 2026, to shareholders of record as of June 30, 2026, demonstrating the company's ongoing profitability and commitment to shareholder returns.
- SM Energy Dividend: SM Energy's Board approved a cash dividend of $0.22 per share, to be paid on June 22, 2026, to shareholders of record as of June 8, 2026, reflecting the company's efforts in maintaining stable cash flow.
- Terex Dividend: Terex announced a quarterly dividend of $0.17 per share, payable on June 22, 2026, to shareholders of record as of June 8, 2026, indicating the company's financial stability in the current market environment.
- Bank of Montreal Dividend: Bank of Montreal's Board declared a quarterly dividend of $1.71 per share, a 4-cent increase from the previous quarter and a 5% increase from the prior year, showcasing the company's proactive measures in enhancing shareholder returns.
See More
Merck Declares Q3 2026 Dividend of $0.85
- Quarterly Dividend Announcement: Merck's Board of Directors has declared a quarterly dividend of $0.85 per share for Q3 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Payment Schedule: The dividend will be paid on July 8, 2026, to shareholders of record as of June 15, 2026, ensuring timely returns for investors and bolstering their confidence in the company.
- Company Vision and Mission: With over 130 years of history, Merck is dedicated to leveraging cutting-edge science to improve lives globally, showcasing its leadership in the biopharmaceutical sector and pursuit of innovative health solutions.
- Risks and Uncertainties: The company highlights various risks in its forward-looking statements, including industry competition, economic fluctuations, and regulatory challenges, which could impact future performance, necessitating investor vigilance.
See More
Adcendo Partners with MSD for Phase Ib Trial of ADCE-T02 with KEYTRUDA
- Clinical Trial Collaboration: Adcendo has entered into an agreement with MSD to initiate a Phase Ib clinical trial in the second half of 2026, evaluating the safety and preliminary efficacy of ADCE-T02 in combination with KEYTRUDA for advanced solid tumors, indicating the potential for enhanced clinical outcomes through complementary mechanisms.
- Drug Supply Arrangement: Under the terms of the agreement, MSD will supply its anti-PD-1 therapy KEYTRUDA, while Adcendo will act as the sponsor for the clinical trial, ensuring smooth execution and allowing both parties to retain commercial rights to their respective compounds, thereby enhancing their market competitiveness.
- Targeted Therapy Potential: ADCE-T02 is an antibody-drug conjugate targeting Tissue Factor (TF), showing promise in various cancers with high unmet medical needs, particularly in tumors such as head and neck squamous cell carcinoma and non-small cell lung cancer, potentially offering new treatment options for patients.
- R&D Strategic Positioning: Adcendo is advancing three ADCs, with ADCE-T02 as the leading candidate targeting Tissue Factor, and the combination with MSD's KEYTRUDA may open new avenues in cancer treatment, further solidifying Adcendo's position in the biopharmaceutical sector.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Three Great Dividend Stocks to Buy and Hold for the Next Decade
- Merck's Drug Pipeline: Merck (MRK) is facing the loss of U.S. patent protection for its cancer drug Keytruda by 2028, yet the company is strategically acquiring Verona Pharma and Terns Pharmaceuticals, potentially adding up to $4 billion in annual revenue from new treatments, indicating strong growth prospects over the next decade.
- Verizon's Stability: Verizon (VZ) is expected to add between 750,000 and 1 million net postpaid customers this year in a mature wireless market, and with a 5.72% dividend yield and 19 consecutive years of dividend increases, it remains a solid investment choice despite slow market growth.
- Equinix's Growth Potential: Equinix (EQIX), a data center operator, reported $2.44 billion in revenue last year, a 10% year-over-year increase, and the AI data center industry is projected to grow at an average annual rate of 25%, enhancing its appeal as a high-dividend stock.
- Attraction of Dividend Growth: All three companies demonstrate strong dividend growth potential, with Merck and Equinix boasting 11 and 19 years of dividend history respectively, suggesting they will continue to provide stable cash flow to investors over the next decade.
See More
Multiple Companies Declare Quarterly Dividends
- Deere Dividend: Deere's Board of Directors declared a quarterly dividend of $1.62 per share, payable on August 10, 2026, to shareholders of record as of June 30, 2026, demonstrating the company's ongoing profitability and commitment to shareholder returns.
- SM Energy Dividend: SM Energy's Board approved a cash dividend of $0.22 per share, to be paid on June 22, 2026, to shareholders of record as of June 8, 2026, reflecting the company's efforts in maintaining stable cash flow.
- Terex Dividend: Terex announced a quarterly dividend of $0.17 per share, payable on June 22, 2026, to shareholders of record as of June 8, 2026, indicating the company's financial stability in the current market environment.
- Bank of Montreal Dividend: Bank of Montreal's Board declared a quarterly dividend of $1.71 per share, a 4-cent increase from the previous quarter and a 5% increase from the prior year, showcasing the company's proactive measures in enhancing shareholder returns.
See More
Merck Declares Q3 2026 Dividend of $0.85
- Quarterly Dividend Announcement: Merck's Board of Directors has declared a quarterly dividend of $0.85 per share for Q3 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Payment Schedule: The dividend will be paid on July 8, 2026, to shareholders of record as of June 15, 2026, ensuring timely returns for investors and bolstering their confidence in the company.
- Company Vision and Mission: With over 130 years of history, Merck is dedicated to leveraging cutting-edge science to improve lives globally, showcasing its leadership in the biopharmaceutical sector and pursuit of innovative health solutions.
- Risks and Uncertainties: The company highlights various risks in its forward-looking statements, including industry competition, economic fluctuations, and regulatory challenges, which could impact future performance, necessitating investor vigilance.
See More
Adcendo Partners with MSD for Phase Ib Trial of ADCE-T02 with KEYTRUDA
- Clinical Trial Collaboration: Adcendo has entered into an agreement with MSD to initiate a Phase Ib clinical trial in the second half of 2026, evaluating the safety and preliminary efficacy of ADCE-T02 in combination with KEYTRUDA for advanced solid tumors, indicating the potential for enhanced clinical outcomes through complementary mechanisms.
- Drug Supply Arrangement: Under the terms of the agreement, MSD will supply its anti-PD-1 therapy KEYTRUDA, while Adcendo will act as the sponsor for the clinical trial, ensuring smooth execution and allowing both parties to retain commercial rights to their respective compounds, thereby enhancing their market competitiveness.
- Targeted Therapy Potential: ADCE-T02 is an antibody-drug conjugate targeting Tissue Factor (TF), showing promise in various cancers with high unmet medical needs, particularly in tumors such as head and neck squamous cell carcinoma and non-small cell lung cancer, potentially offering new treatment options for patients.
- R&D Strategic Positioning: Adcendo is advancing three ADCs, with ADCE-T02 as the leading candidate targeting Tissue Factor, and the combination with MSD's KEYTRUDA may open new avenues in cancer treatment, further solidifying Adcendo's position in the biopharmaceutical sector.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Three Great Dividend Stocks to Buy and Hold for the Next Decade
- Merck's Drug Pipeline: Merck (MRK) is facing the loss of U.S. patent protection for its cancer drug Keytruda by 2028, yet the company is strategically acquiring Verona Pharma and Terns Pharmaceuticals, potentially adding up to $4 billion in annual revenue from new treatments, indicating strong growth prospects over the next decade.
- Verizon's Stability: Verizon (VZ) is expected to add between 750,000 and 1 million net postpaid customers this year in a mature wireless market, and with a 5.72% dividend yield and 19 consecutive years of dividend increases, it remains a solid investment choice despite slow market growth.
- Equinix's Growth Potential: Equinix (EQIX), a data center operator, reported $2.44 billion in revenue last year, a 10% year-over-year increase, and the AI data center industry is projected to grow at an average annual rate of 25%, enhancing its appeal as a high-dividend stock.
- Attraction of Dividend Growth: All three companies demonstrate strong dividend growth potential, with Merck and Equinix boasting 11 and 19 years of dividend history respectively, suggesting they will continue to provide stable cash flow to investors over the next decade.
See More
